

UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

Aurobindo Pharma USA Inc.  
Petitioners,

v.

Andrx Labs, LLC  
Patent Owner

---

Case IPR2017-01648  
U.S. Patent No. 6,866,866

---

**PATENT OWNER'S PRELIMINARY RESPONSE  
UNDER 37 C.F.R. § 42.107**

**TABLE OF CONTENTS**

I. Introduction..... 1

II. Background.....5

    A. State of the Art in November 2000 .....5

    B. Clinical Development and Approval of Fortamet® .....6

    C. The '866 Patent .....7

    D. Litigation Involving the '866 Patent .....10

    E. Alleged Prior Art Relied on by Petitioner.....12

III. Level of Ordinary Skill in the Art .....15

IV. Claim Construction.....16

    A. “Membrane” .....16

    B. “Dinnertime” or “At Dinner” .....18

    C. “T<sub>max</sub>” .....18

    D. Other Claim Terms Not Requiring Construction.....19

V. The Petition Fails to Establish a Reasonable Likelihood that Any of Claims 1-25 is Anticipated by Chen (Ground I).....19

VI. The Petition Fails to Establish a Reasonable Likelihood that Any of Claims 1-3 is Anticipated by Timmins (Ground II) .....21

    A. Ground II Should Be Denied Because the Petition Does Not Apply the Correct Legal Standard for the Anticipation of a Claimed Range By an Overlapping Prior Art Range.....21

        1. A Claim to a Range is Anticipated By a Prior Art Disclosure of an Overlapping Range Only Where There Is No Reasonable Difference in How the Invention Operates Over the Ranges ...21

        2. Petitioner Contends that Timmins Discloses a Range of Mean T<sub>max</sub> Values, Rather Than Specific Mean T<sub>max</sub> Values Within That Range .....22

        3. Petitioner Fails to Sufficiently Show How the Range of Mean T<sub>max</sub> Values Allegedly Disclosed By Timmins Anticipates the Claimed Range.....24

    B. Ground II Should Also Be Denied Because it Presents the Same Prior Art that Previously Was Considered and Rejected By the Patent Office.....25

VII. The Petition Fails to Establish a Reasonable Likelihood that Any of Claims 1-25 is Obvious Over Cheng in View of Timmins (Ground III) .....26

VIII. Objective Indicia Support the Non-Obviousness of the Challenged Claims .....30

IX. Conclusion .....33

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>Cases</b>	
<i>Atofina v. Great Lakes Chemical Corp.</i> , 441 F.3d 991 (Fed. Cir. 2006) .....	4, 21, 22, 24
<i>ClearValue, Inc. v. Pearl River Polymers, Inc.</i> , 668 F.3d 1340 (Fed. Cir. 2012) .....	4, 22
<i>INEOS USA LLC v. Berry Plastics Corp.</i> , 783 F.3d 865 (Fed. Cir. 2015) .....	3, 22, 24
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Patent Litigation</i> , 676 F.3d 1063 (Fed. Cir. 2012) .....	27
<i>In re Katz</i> , 687 F.2d 450 (C.C.P.A. 1982) .....	20
<i>Kinetic Technologies, Inc. v. Skyworks Solutions, Inc.</i> , IPR2014-00529, Paper 8 (P.T.A.B. Sept. 23, 2014).....	5
<i>Sinorgchem Co. v. International Trade Commission</i> , 511 F.3d 1132 (Fed. Cir. 2007) .....	17, 18
<i>Tessera, Inc. v. Internatonal Trade Commission</i> , 646 F.3d 1357 (Fed. Cir. 2011) .....	21
<i>Titanium Metals Corp. v. Banner</i> , 778 F.2d 775 (Fed. Cir. 1985) .....	22
<b>Docketed Cases</b>	
<i>Sciele Pharma Inc. et al. v. Lupin Ltd., et al.</i> , No. 2012-1228 (Fed. Cir.) .....	11
<i>Sciele Pharma, Inc. et al v. Lupin Ltd. et al.</i> , No. 1-09-cv-00105 (D. Md.).....	11
<i>Sciele Pharma, Inc. v. Lupin Ltd.</i> , Civ. Act. No. 09-0037 (D. Del.) .....	11

*Shionogi Inc. and Andrx Labs. L.L.C. v. Aurobindo Pharma Ltd. et al.*,  
Civ. Act. No. 1:17-cv-00072-MSG (D. Del.) ..... 10

*Shionogi Inc. et al. v. Nostrum Laboratories, Inc., et al.*,  
1:12-cv-04402 (D.N.J.)..... 12

*Shionogi Inc. et al. v. Qingdao Baheal Pharmaceutical Co. Ltd.*,  
Civ. Act. No. 17-cv-1347-MSG (D. Del.) ..... 11

*Shionogi Pharma v. Mylan, Inc.*,  
Civ. Act. No. 10-135 (D. Del.) ..... 11

*Takeda Pharmaceutical Co., Ltd., et. al. v. Mylan, Inc., et. al.*,  
No. 2-12-cv-00026 (W.D. Pa.) ..... 12

*Takeda Pharmaceutical Company Limited et al v. Mylan, Inc. et al.*,  
No. 1-12-cv-00024 (S.D.N.Y.) ..... 12

*Takeda Pharmaceutical Company Limited et al v. Mylan, Inc. et al.*,  
No. 1-12-cv-02038 (S.D.N.Y.) ..... 12

**Statutes, Codes & Regulations**

35 U.S.C. § 102(g) ..... 20

35 U.S.C. § 314..... 1

37 C.F.R. § 42.108 ..... 1

American Inventors Protection Act of 1999 ..... 20

Intellectual Property and High Technology Technical Amendments  
Act of 2002 ..... 20

**Other Authorities**

December 11, 2002 Examination Guidelines for 35 U.S.C. § 102(e) ..... 20

MPEP § 706.02(F)(1)(I)(C)(3)..... 19, 20

MPEP § 2132(III)..... 20

MPEP § 2136.04 ..... 20

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.